October 25th,2021/IndustryNewsGlobal/ — This new report from Stratview Research analyses the Sickle Cell Market over the trend period from 2016 to 2019 and forecast period from 2022 to 2026. The insights of the report shall enable informed decision making and strategy formulation for the near future to capitalize on the opportunities.

Sickle Cell Market Overview:

The sudden outbreak of the COVID-19 has led to unforeseen fluctuations across many industries and the Sickle Cell Market is no different. Derived from the previous market scenario, the Sickle Cell Market is estimated to grow from USD xx million in 2020 to USD xx million by 2026 at a healthy CAGR of x% during the forecast period but with the global crisis in action, the growth curve has deviated from its expected path and exhibits an uncertain trajectory at present. 

COVID-19 Impact on Global Sickle Cell Market

The covid-19 outbreak posed significant challenges to the health care system across geographies. It affected the growth of the sickle cell market negatively as patients postponed their appointments due to a rapid surge in covid-19 cases across geographies. Also, supply chain disruptions due to the imposition of lockdown affected the market growth further.

Key Players:

  • Bluebird bio, Inc. (The U.S),
  • Eli Lilly and Company (The U.S),
  • Gilead Sciences, Inc. (The U.S),
  • Merck & Co., Inc. (The U.S),
  • Novartis International AG (Switzerland),
  • Sanofi S.A. (France),
  • Baxter International Inc. (The U.S),
  • Bristol-Myers Squibb (The U.S),
  • Global Blood Therapeutics (The U.S),
  • Johnson & Johnson (The U.S),
  • Mast Therapeutics (The U.S), and
  • Pfizer, Inc. (The U.S).

The Sickle Cell Market is segmented by–

  • By Therapy (Bone Marrow Transplant, Medications, Blood Transfusion, Gene Therapy), 
  • By End-User (Hospital, Clinic, Home Healthcare),
  • Region (North America, Europe, Asia-Pacific, and Rest of the World).

Get access to a deeper coverage of the impact of COVID-19 on this Market here: https://www.stratviewresearch.com/Request-Sample/1811/sickle-cell-market.html#form

Regional analysis:

The market in North America accounted for the largest share in 2020 and is projected to register significant growth during the review period.

  • The regional market growth can be attributed to the availability of required infrastructure and technologies to treat the patients having the sickle disease.
  • The market in the Asia-Pacific region is projected to register the fastest growth rate on account of rising consumer awareness and advancement in healthcare infrastructure in developing countries.

About Stratview Research

Stratview Research is a global market intelligence firm providing wide range of services including syndicated market reports, custom research and sourcing intelligence across industries, such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas.

For enquiries,
Stratview Research
Direct: +1-313-307-4176